perflutren has been researched along with regadenoson in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdelmoneim, SS; Basu, A; Basu, R; Hagen, ME; Mendrick, E; Mulvagh, SL; Norby, B; Pattan, V; Roberson, T; Szydel, T; Wong, B | 1 |
1 review(s) available for perflutren and regadenoson
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for perflutren and regadenoson
| Article | Year |
|---|---|
Acute hyperglycemia reduces myocardial blood flow reserve and the magnitude of reduction is associated with insulin resistance: a study in nondiabetic humans using contrast echocardiography.
Topics: Acute Disease; Adult; Biomarkers; Blood Glucose; Contrast Media; Coronary Circulation; Echocardiography; Female; Fluorocarbons; Glucose Clamp Technique; Humans; Hyperglycemia; Insulin Resistance; Male; Middle Aged; Observer Variation; Predictive Value of Tests; Purines; Pyrazoles; Reproducibility of Results; Time Factors; Vasodilator Agents | 2013 |